Covid-19 roundup: WHO rec­om­mends against 'high cost' remde­sivir, dis­ap­point­ing Gilead; EU deals with Pfiz­er/BioN­Tech, Cure­Vac top $10B — re­port

Vek­lury, or remde­sivir, may be the first Covid-19 treat­ment to earn full ap­proval at the FDA, af­ter it won a full-throat­ed en­dorse­ment from Pres­i­dent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.